Skip to main content
Atrás
Watch Compare

Indaptus Therapeutics, Inc.

Calidad de datos: 83%
INDP
Nasdaq Manufacturing Chemicals
$2.11
▲ $0.26 (14.05%)
Cap. Mercado: 4.15 M
Precio
$1.85
Cap. Mercado
4.15 M
Rango del Día
—
Rango de 52 Semanas
—
Volumen
—
Apertura —
Promedio 50D / 200D
—
Promedio 50D / 200D
—

Quick Summary

Puntos Clave

Negative free cash flow of -14.82 M

Crecimiento

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Calidad

Return on Equity
-1421.98%
Below sector avg (-53.47%)
ROIC-1068.66%
Net MarginN/A
Op. MarginN/A

Seguridad

Debt / Equity
N/A
Current Ratio2.88
Interest CoverageN/A

Valoración

PE (TTM)
-0.20
Above sector avg (-1.48)
P/B Ratio0.90
EV/EBITDAN/A
Dividend YieldN/A

Historial de Precios

Tendencias Financieras

Comparación con Pares

vs mediana del sector Manufacturing (1364 pares)
Métrica Acción Mediana del Sector
P/E -0.2 -1.5
P/B 0.9 1.6
ROE % -1422.0 -53.5
Net Margin % — -41.5
Rev Growth 5Y % — 1.8
D/E — 0.3

Precio Objetivo de Analistas

1 analista
Hold
Actual
$2.11
+373.9%
Objetivo
$10.00
$10.00
$10.00
$10.00
Pronóstico
EPS Futuro -$4.48
Ingresos Est. 0.0

Estimaciones de Ganancias

Período EPS Est. Ingresos Est. Analistas
FY2027 -$4.48
-$4.48 – -$4.48
 0.0 1
FY2026 -$6.43
-$6.43 – -$6.43
 0.0 1

Sorpresas de Ganancias

Últimos 4 trimestres
Trimestre EPS Est. EPS Real Sorpresa
Q42025 -$4.36 -$9.19 -110.8%
Q32025 -$4.17 -$2.98 +28.5%
Q22025 -$9.24 -$9.09 +1.6%
Q12025 -$5.04 -$8.96 -77.8%

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -20.85 M
ROE -1421.98% ROA -304.83%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -14.82 M
ROIC -1068.66% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 2.88
Interest Coverage N/A Asset Turnover N/A
Working Capital 4.20 M Tangible Book Value 4.61 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -0.20 Forward P/E N/A
P/B Ratio 0.90 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -357.33%
Market Cap 4.15 M Enterprise Value -1.68 M
Per Share
EPS (Diluted TTM) -21.58 Revenue / Share N/A
FCF / Share -6.61 OCF / Share -6.61
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 71.10%
SBC-Adj. FCF -15.84 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue — — — — —
Net Income -20.85 M -15.02 M -15.42 M -14.32 M -7.71 M
EPS (Diluted) -21.58 -1.61 -1.83 — —
Gross Profit — — — — —
Operating Income -19.83 M -15.37 M -16.38 M -14.91 M -7.73 M
EBITDA — — — — —
R&D Expenses 9.34 M 7.25 M 7.62 M 6.32 M 2.52 M
SG&A Expenses — — — — —
D&A — — — — —
Interest Expense — — — — —
Income Tax 1,716.0 1,700.0 2,450.0 30.0 1,650.0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 9.31 M 7.34 M 14.92 M 28.06 M 40.58 M
Total Liabilities — 3.39 M 2.85 M 3.43 M 4.68 M
Shareholders' Equity 3.15 M 3.94 M 12.08 M 24.63 M 35.90 M
Total Debt — — — — —
Cash & Equivalents 8.51 M 5.79 M 13.36 M 9.63 M 39.13 M
Current Assets 9.31 M 6.62 M 14.00 M 27.24 M 40.39 M
Current Liabilities 6.16 M 3.39 M 2.77 M 3.43 M 4.60 M